Back to News
Nov 24, 2025 4:00 PM

AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows

Hong Kong-based Harbour BioMed announced on Sunday an update and advancement of its global strategic collaboration with AstraZeneca Plc (NASDAQ:AZN), initially established in March 2025.

• AZN is in positive territory. Get the market research here.

Harbour BioMed is a biopharmaceutical company focused on the discovery and development of antibody therapeutics in immunology and oncology.

The collaboration aims to discover and develop next-generation biotherapeutics, including antibody-drug conjugates and T cell engagers.

Under the terms of the agreement, AstraZeneca will continue to nominate discovery programs to Harbour BioMed each year over the next four years, reflecting the continued progress of the partnership, and will retain the option to license these programs for further development. 

Harbour BioMed will be eligible to receive option and option exercise fees, development and commercial milestone payments, plus tiered royalties on future net sales on such licensed programs.

The economic terms are consistent with the financial framework established in March 2025.

Also ...